| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.5 - $42.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
189,781 |
290,198 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,334,261 |
$12,063,571 |
| Total People Sold |
1 |
1 |
15 |
16 |
| Total Sell Transactions |
3 |
3 |
34 |
58 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hastings Paul J |
Director |
– • – |
2016-06-06 |
4 |
AS |
$46.95 |
$53,335 |
D/D |
(1,136) |
1,717 |
|
- |
|
| Brege Laura |
Director |
– • – |
2016-06-06 |
4 |
AS |
$46.95 |
$46,950 |
D/D |
(1,000) |
1,000 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2016-04-15 |
4 |
AS |
$63.97 |
$1,603,378 |
D/D |
(25,000) |
285 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2016-04-15 |
4 |
OE |
$5.49 |
$137,250 |
D/D |
25,000 |
25,285 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2016-02-17 |
4 |
AS |
$60.00 |
$180,000 |
D/D |
(3,000) |
2,853 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2016-02-17 |
4 |
OE |
$10.81 |
$38,770 |
D/D |
3,000 |
5,853 |
|
- |
|
| Braunstein Scott |
SVP, Strategy & Corp. Dev. |
• – – |
2016-01-29 |
4 |
B |
$58.92 |
$117,840 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Jones James B |
SVP & Chief Medical Officer |
• – – |
2016-01-27 |
4 |
B |
$62.50 |
$31,250 |
D/D |
500 |
1,500 |
2.74 |
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2016-01-15 |
4 |
AS |
$62.55 |
$957,592 |
D/D |
(15,000) |
285 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2016-01-15 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
15,285 |
|
- |
|
| Jones James B |
SVP & Chief Medical Officer |
• – – |
2016-01-12 |
4 |
B |
$66.00 |
$66,000 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
| Longenecker John P Phd |
Director |
– • – |
2016-01-12 |
4 |
B |
$66.55 |
$19,965 |
D/D |
300 |
2,300 |
2.39 |
- |
|
| Hastings Paul J |
Director |
– • – |
2015-11-20 |
4 |
AS |
$60.00 |
$180,000 |
D/D |
(3,000) |
2,853 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2015-11-20 |
4 |
OE |
$10.81 |
$32,430 |
D/D |
3,000 |
5,853 |
|
- |
|
| Stack David M |
President, CEO and Chairman |
• • – |
2015-10-15 |
4 |
AS |
$37.11 |
$563,561 |
D/D |
(15,000) |
176 |
|
- |
|
| Stack David M |
President, CEO and Chairman |
• • – |
2015-10-15 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
15,176 |
|
- |
|
| Scibetta James S |
SVP, Chief Financial Officer |
• – – |
2015-09-11 |
4 |
B |
$61.37 |
$306,850 |
D/D |
5,000 |
10,504 |
2.74 |
- |
|
| Hastings Paul J |
Director |
– • – |
2015-08-17 |
4 |
AS |
$60.02 |
$180,060 |
D/D |
(3,000) |
2,853 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2015-08-17 |
4 |
OE |
$10.81 |
$32,430 |
D/D |
3,000 |
5,853 |
|
- |
|
| Stack David M |
President, CEO and Chairman |
• • – |
2015-07-15 |
4 |
AS |
$67.78 |
$1,016,700 |
D/D |
(15,000) |
176 |
|
- |
|
| Stack David M |
President, CEO and Chairman |
• • – |
2015-07-15 |
4 |
OE |
$1.61 |
$24,150 |
D/D |
15,000 |
15,176 |
|
- |
|
| Riker Lauren Bullaro |
Vice President, Finance |
• – – |
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
5,980 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
4,645 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
3,850 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2015-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,853 |
|
- |
|
781 Records found
|
|
Page 20 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.44 (1.45%) 
